NCT05731843View on ClinicalTrials.gov

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions
Healthy Volunteer Study
Interventions
DRUG

Cohort 1 BEM + Ruzasvir

Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions

DRUG

Cohort 2 Ruzasvir + BEM

Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions

Trial Locations (1)

Unknown

Atea Study Site, Québec

Sponsors
All Listed Sponsors
lead

Atea Pharmaceuticals, Inc.

INDUSTRY